Gena Wang
Stock Analyst at Barclays
(2.32)
# 2,554
Out of 4,902 analysts
204
Total ratings
41.48%
Success rate
-1.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: Overweight | $29 → $32 | $18.25 | +75.39% | 11 | Jul 17, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Overweight | $51 → $57 | $42.00 | +35.71% | 10 | Jul 1, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $57 → $59 | $34.93 | +68.91% | 3 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $15 → $10 | $6.22 | +60.77% | 7 | May 16, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $9 → $5 | $0.49 | +920.41% | 4 | May 14, 2025 | |
| CLLS Cellectis | Maintains: Overweight | $5 → $4 | $1.90 | +111.08% | 4 | May 13, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $56 → $42 | $64.05 | -34.43% | 16 | May 9, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $45 → $38 | $4.41 | +761.68% | 2 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $56 → $42 | $48.15 | -12.77% | 15 | May 8, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $55 → $53 | $38.03 | +39.36% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $8.65 | +27.17% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $31 → $25 | $21.26 | +17.59% | 9 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $40 | $31.82 | +25.71% | 9 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.47 | +467.25% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $12.47 | +108.50% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $465.49 | +0.32% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.82 | +6.57% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $3 → $4 | $5.50 | -27.27% | 8 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $295 → $329 | $322.44 | +2.03% | 7 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $58.35 | +47.39% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $50 | $8.53 | +486.17% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $26.97 | +200.33% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $42.76 | +119.83% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $14.53 | -38.04% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $13.64 | +83.28% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.71 | +106.78% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $3.38 | +166.67% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $6.86 | +3,908.75% | 1 | Jan 6, 2017 |
Sarepta Therapeutics
Jul 17, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $18.25
Upside: +75.39%
Ionis Pharmaceuticals
Jul 1, 2025
Upgrades: Overweight
Price Target: $51 → $57
Current: $42.00
Upside: +35.71%
Avidity Biosciences
Jun 10, 2025
Maintains: Overweight
Price Target: $57 → $59
Current: $34.93
Upside: +68.91%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $6.22
Upside: +60.77%
Sangamo Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.49
Upside: +920.41%
Cellectis
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.90
Upside: +111.08%
CRISPR Therapeutics AG
May 9, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $64.05
Upside: -34.43%
4D Molecular Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $4.41
Upside: +761.68%
PTC Therapeutics
May 8, 2025
Maintains: Equal-Weight
Price Target: $56 → $42
Current: $48.15
Upside: -12.77%
Cytokinetics
May 8, 2025
Maintains: Overweight
Price Target: $55 → $53
Current: $38.03
Upside: +39.36%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $8.65
Upside: +27.17%
May 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $21.26
Upside: +17.59%
May 2, 2025
Maintains: Equal-Weight
Price Target: $45 → $40
Current: $31.82
Upside: +25.71%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.47
Upside: +467.25%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $12.47
Upside: +108.50%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $465.49
Upside: +0.32%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.82
Upside: +6.57%
Nov 15, 2024
Maintains: Underweight
Price Target: $3 → $4
Current: $5.50
Upside: -27.27%
Nov 1, 2024
Maintains: Overweight
Price Target: $295 → $329
Current: $322.44
Upside: +2.03%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $58.35
Upside: +47.39%
Aug 5, 2024
Maintains: Overweight
Price Target: $55 → $50
Current: $8.53
Upside: +486.17%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $26.97
Upside: +200.33%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $42.76
Upside: +119.83%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $14.53
Upside: -38.04%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $13.64
Upside: +83.28%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.71
Upside: +106.78%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $3.38
Upside: +166.67%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $6.86
Upside: +3,908.75%